The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey.

"Disclosure of potential conflict of interest Polina Pyatilova has no relevant conflict of interest in relation to this work. Jonathan A. Bernstein has no relevant conflict of interest in relation to this work. Outside of it, JB was a PI and/or consultant for Blueprint Medicine and Cogent pharmaceuticals; AIM center of excellence, president AAAAI, member of JTF guideline committee. Saša Dimitrijević and Gerard Hoehn are employees and equity holders of Blueprint Medicines Corporation. Marcus Maurer has no relevant conflict of interest in relation to this work. Outside of it, MM is or recently was a speaker and/or advisor or received institutional research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Noucor, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio and UCB. Pavel Kolkhir has no relevant conflict of interest in relation to this work. Outside of it, PK is or recently was a speaker and/or advisor for Novartis, Roche and ValenzaBio. Frank Siebenhaar has no relevant conflict of interest in relation to this work. Outside of it, FS is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint Medicine, Celldex, Cogent, Escient, Granular, GSK, Invea, Noucor, Novartis, Moxie, Sanofi/Regeneron and Third Harmonic Bio."